Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Cancer Prev Res (Phila). 2010 Jan;3(1):25–34. doi: 10.1158/1940-6207.CAPR-09-0200

Fig. 2.

Fig. 2

Cellular proliferation assay. Celecoxib at 10 and 20 μmol/L selectively inhibits BCC cell line proliferation (ASZ, BSZ, and CSZ) compared with non-BCC keratinocytes (C5N). Columns, mean; bars, SE. *, P < 0.05; †, P < 0.01, for difference between BCC versus C5N non-BCC keratinocyte cell line.